Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study

References

• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi:10.21037/tlcr.2016.06.0727413711
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237. doi:10.1002/cncr.1188214716755
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm. 2009;15(8):669–682. doi:10.18553/jmcp.2009.15.8.66919803556
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–170. doi:10.1056/NEJM1991071832503051711156
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29(3):319–324. doi:10.1016/0959-8049(93)90376-Q
   Web of Science ®Google Scholar
• Li L, Ma S, Wu M, Tan X, Zhong S, Lang J. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study. BMJ Support Palliat Care. 2019;9(4):373–380. doi:10.1136/bmjspcare-2019-001862
   PubMed Web of Science ®Google Scholar
• Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(Suppl 1):1–15. doi:10.2165/00003495-200262001-00001
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129–146. doi:10.1016/j.critrevonc.2004.01.00115157662
   PubMed Web of Science ®Google Scholar
• Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy. 2004;24(4):488–494. doi:10.1592/phco.24.5.488.3336015098803
   PubMed Web of Science ®Google Scholar
• Bozcuk H, Yıldız M, Artaç M, et al. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Support Care Cancer. 2015;23(6):1759–1767. doi:10.1007/s00520-014-2531-625433439
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427–437. doi:10.1634/theoncologist.10-6-42715967836
   PubMed Web of Science ®Google Scholar
• Cao X, Ganti AK, Stinchcombe T, et al. Predicting risk of chemotherapy-induced severe neutropenia: a pooled analysis in individual patients data with advanced lung cancer. Lung Cancer. 2020;141:14–20. doi:10.1016/j.lungcan.2020.01.00431926983
   PubMed Web of Science ®Google Scholar
• Gjafa E, Ng K, Grunewald T, et al. Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimen. BJU Int. 2020;127:205–211. doi:10.1111/bju.1517532668505
   PubMed Web of Science ®Google Scholar
• Kouranos V, Dimopoulos G, Vassias A, Syrigos KN. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis. Cancer Lett. 2011;313(1):9–14. doi:10.1016/j.canlet.2011.08.02421955615
   PubMed Web of Science ®Google Scholar
• Lombard A, Mistry H, Aarons L, Ogungbenro K. Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2020. doi:10.1111/bcp.14614
   PubMed Web of Science ®Google Scholar
• Atasilp C, Chansriwong P, Sirachainan E, et al. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Sci Rep. 2020;10(1):13486. doi:10.1038/s41598-020-70351-032778670
   PubMed Web of Science ®Google Scholar
• Choi JH, Choi J, Chung SM, et al. The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma. Tuberc Respir Dis (Seoul). 2019;82(3):211–216. doi:10.4046/trd.2018.001930841020
   PubMed Web of Science ®Google Scholar
• Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer. 2012;107(9):1525–1533. doi:10.1038/bjc.2012.42122990653
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Oshika Y, Obara K, Tanaka Y, Shimizu E. [A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy]. Gan Kagaku Ryoho. 2010;37(8):1553–1556. Japanese.
   PubMedGoogle Scholar
• Nishio M, Ohyanagi F, Taguch F, et al. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Lung Cancer. 2005;48(1):115–119. doi:10.1016/j.lungcan.2004.09.00615777978
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization; 1979.
   Google Scholar
• Epstein RS, Aapro MS, Basu Roy UK, et al. Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther. 2020;37(8):3606–3618. doi:10.1007/s12325-020-01419-632642965
   PubMed Web of Science ®Google Scholar
• Videtic G, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(5):295–301. doi:10.1016/j.prro.2017.04.01428596092
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Andratschke N, Dieckmann K, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017;124(1):11–17. doi:10.1016/j.radonc.2017.05.01228687397
   PubMed Web of Science ®Google Scholar
• Kattan MW, Scardino PT. Evidence for the usefulness of nomograms. Nat Clin Pract Urol. 2007;4(12):638–639. doi:10.1038/ncpuro096817984994
   PubMedGoogle Scholar
• Vickers AJ, Cronin AM. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 2010;76(6):1298–1301. doi:10.1016/j.urology.2010.06.01921030068
   PubMed Web of Science ®Google Scholar